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PVIEWPOINT
Promise of Blood- and Bone Marrow-Derived
Stem Cell Transplantation for Functional Cardiac Repair
Putting It in Perspective With Existing Therapy
Thorsten Reffelmann, MD,*†‡ Stephanie Könemann, MD,* Robert A. Kloner, MD, PHD, FACC†‡
Greifswald, Germany; and Los Angeles, California
Intracoronary transplantation of peripheral blood- or bone marrow-derived cells, as tested in several recent trials,
is associated with moderate increases in left ventricular (LV) ejection fraction (EF) and a small reduction of LV
end-systolic volumes. Substantial variability exists between trials, and most of them are based on a small num-
ber of patients. Meta-analyses estimated an increase in EF of 3% to 4% more in comparison with control pa-
tients. In this review, the effects are put into perspective with established treatment options for acute myocar-
dial infarction (AMI), such as thrombolysis and acute percutaneous interventions or pharmacotherapy aimed at
favorably influencing the cardiac remodeling process. Changes in functional and morphometric parameters of LV
performance after cell therapy appear to be in the range of effects observed with reperfusion therapy, pharma-
cotherapeutic interventions influencing the renin-angiotensin-aldosterone pathway, and beta-blockers after
AMI. (J Am Coll Cardiol 2009;53:305–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.018C
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(fter the comprehensive scientific validation of reperfusion
herapy for the treatment of acute myocardial infarction
AMI) and the seminal advances in pharmacotherapy tar-
eting left ventricular (LV) remodeling after a cardiac insult
hat were accomplished in the second half of the 20th
entury, any innovative therapy for AMI and its conse-
uences will be compared with the progress made in the
ast. Many of the early landmark trials demonstrated
onvincing benefit in terms of clinical end points (1–4).
ome of the initial studies were accompanied by parallel
nalyses in which functional and morphometric parameters
ere used as correlates for clinical end points.
In the majority of clinical trials investigating the effects of
ntracoronary cell transplantation, the primary end point
omprises changes in LV volumes and EF in comparison
ith a control group over time (5–7). In the following
iscussion, the effects of intracoronary transplantation of
one marrow- and blood-derived stem cells in AMI on
unctional and morphometric LV parameters are put into
he context of established therapy, such as reperfusion
herapy and adjunctive pharmacotherapy.
rom the *Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der
rnst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany; and †The Heart
nstitute, Good Samaritan Hospital, and the ‡Division of Cardiology, Keck School of
edicine, University of Southern California, Los Angeles, California.t
Manuscript received June 20, 2008; revised manuscript received October 9, 2008,
ccepted October 13, 2008.urrent State of Clinical
ork on Transplantation of Bone Marrow-
nd Peripheral Blood-Derived Stem Cells
able 1 (8–20) summarizes LV ejection fraction (EF) at
aseline and latest available follow-up in the control group
nd transplantation group in 13 trials of intracoronary
ransplantation performed in AMI (8–20).
A meta-analysis by Lipinski et al. (5) included 10 of these
rials (7 randomized, 3 cohort studies) on intracoronary cell
njection (within the first 14 days after infarction), yielding
98 patients, of which 659 were available at follow-up
median follow-up of 6 months). In 2 trials (n  126),
eripheral blood cells were used for intracoronary infusion
nd in 8 investigations bone marrow-derived cells were
sed. For the pooled population, Lipinski et al. (5) found a
ignificantly superior improvement in LVEF of 3.0% (95%
onfidence interval: 1.9% to 4.1%, p 0.00001) for subjects
eceiving bone marrow transplantation in comparison with
ontrol subjects. Similarly, LV end-systolic volumes were
educed in patients receiving cell therapy by –7.4 ml (95%
onfidence interval: –12.2 to –2.7 ml, p  0.002) compared
ith control subjects. Changes in end-diastolic volumes
ere not significantly different between groups in this
eta-analysis.
Clinical end points, such as death, target vessel revascu-
arization, and rehospitalization for heart failure, did not
ignificantly differ between groups of the pooled population
xcept for the incidence of recurrent myocardial infarction
MI). The reduction of reinfarction in the cell transplanta-
ion group was based mainly on the effects reported in the
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Enriched Progenitor Cells and
Infarct Remodeling in Acute
Myocardial Infarction) study
(17,21). Study size in the re-
maining studies was too small for
adequate end point analysis.
Notably, the findings of the
meta-analysis by Lipinski et al.
5) correspond well with another meta-analysis by Abdel-
atif et al. (6) (in part an overlapping, but more heteroge-
eous set of trials), which calculated a mean increase in EF
f 3.66% more in comparison with control subjects.
ow Do Improvements in EF
ith Cell Therapy Compare With
ther Established Treatment Options for AMI?
hrombolysis for AMI. The authors of the ISAM (Intra-
enous Streptokinase in Acute Myocardial Infarction) trial
valuated the effect of intravenous streptokinase application
ithin 6 h after onset of AMI on clinical end points, infarct
ize, and EF (22). LVEF at 3 to 4 weeks was 56.8  0.7%
n the streptokinase group (n  428) but 53.9  0.7% in
ontrol patients (n  420). A pooled analysis of 10
andomized trials of intracoronary and intravenous applica-
ion of streptokinase by Patel et al. (4) (total of 14,355
atients) demonstrated a reduction in mortality within the
rst 6 weeks by thrombolysis, whereas data on LV function
emained inconclusive. Only by analyzing patients with
uccessful reperfusion and without reperfusion separately, a
lear effect toward improvement of LVEF could be dem-
nstrated for patients with successful reperfusion.
mmediate coronary angioplasty for AMI. As an alterna-
ive approach to coronary reperfusion, acute percutaneous
ngioplasty was developed in the early 1990s. In a landmark
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
EF  ejection fraction
LV  left ventricular
MI  myocardial infarction
hanges in LVEF in the Control Groups and Transplantation Groupsf Intracoronary Injection of Blood- or Bo e M rrow-Derived Cells in
Table 1 Changes in LVEF in the Control Groups and Transplantof Intracoronary Injection of Blood- or Bone Marrow-De
Author, Year (Ref. #) n
LVEF (%) Baseline
(Control Group)
LVEF (%) Fol
(Control G
Strauer et al., 2002 (8) 20 60 7 64 7
Bartunek et al., 2005 (9) 35 44 3 49 4
Li et al., 2006 (10) 70 51 8 53 6
Janssens et al., 2006 (11) 67 47 8 49 1
Meyer et al., 2006 (12) 60 51 9 54 1
Kang et al., 2006 (13) 96 53 13 53 1
Ge et al., 2006 (14) 20 58 8 56 4
Lunde et al., 2006 (15) 100 43 12 49 1
Meluzı´n et al., 2006 (16) 66 42 9 44 9
Schächinger et al., 2006 (17) 204 47 10 50 1
Huikuri et al., 2007 (18) 66 62 12 64 1
Chen et al., (2004) (19) 69 48 10 54 5
Ruan et al., (2005) (20) 20 54 7 50 8F  ejection fraction; LV  left ventricular.rial by Zijlstra et al. (23), angioplasty (without stenting)
as associated with a greater coronary patency rate and less
esidual stenosis compared with intravenous streptokinase.
VEF, as assessed by radionuclide scanning before hospital
ischarge, amounted to 45  12% in patients treated with
treptokinase (n  72, time to start of streptokinase infu-
ion: 30  15 min) and 51  11% (p  0.004) in patients
ith immediate angioplasty (n  70, time to first balloon
nflation 61  22 min).
In a multicenter trial in which the authors compared
issue plasminogen activator (n  200) and immediate
ngioplasty (n  195) within 12 h of onset of MI, the
uthors found a lower incidence of death or reinfarction
ithin 6 months for patients with acute angioplasty (16.8%
s. 8.5%, p  0.02) (24). Nonetheless, EF at 6 weeks was
imilar (53  13% vs. 53  13%).
In 1998, Ribichini et al. (25) published a randomized
tudy in which they compared thrombolysis using tissue
lasminogen activator with “liberal stenting” (n  55, 58%
f patients with stent implantation) in patients with acute
nferior MI. At 1 year, the combined incidence of death,
einfarction, and target vessel revascularization was 52.7% in
he thrombolysis group and 11.0% in the angioplasty group
p  0.0001). Parallel to clinical end points, EF was 55.2 
.5% in the percutaneous coronary angioplasty group and
8.2  9.9% in patients treated with plasminogen activator
p  0.0001).
ngiotensin-converting enzyme inhibition and angio-
ensin receptor blockade after MI. In the SAVE (Survival
nd Ventricular Enlargement) study, in which researchers
nvestigated captopril treatment compared with placebo in
urvivors of AMI, a significant reduction in cardiovascular
vents was demonstrated with the use of captopril. The
chocardiographic SAVE substudy (n  785 initially)
llustrated less increase in end-diastolic and -systolic vol-
3 Trialste Myocardial Infarction
Groups in 13 Trials
Cells in Acute Myocardial Infarction
LVEF (%) Baseline
(Transplant Group)
LVEF (%) Follow-Up
(Transplant Group)
(Change of LVEF [%] in
Transplant Group) 
(Change of LVEF [%] in
Control Group)
57 8 62 10 1.0
45 3 52 4 2.8
50 8 57 8 5.5
49 7 52 9 1.1
50 10 56 15 2.8
52 10 57 9 5.2
54 9 59 10 6.7
41 10 49 13 1.4
42 9 (low dose) 45 9 (low dose) 2.0
41 9 (high dose) 46 9 (high dose)
48 9 54 10 2.5
59 8 67 9 6.0
49 9 67 3 12.0
53 9 59 13 9.2in 1Acu
ation
rived
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January 27, 2009:305–8 Cell Transplantation in Perspectivemes as well as less reduction in change in LV areas, as a
easure of EF, over 1 year (Fig. 1) (26).
In the HEART (Healing and Early Afterload Reducing
herapy) trial, 352 patients with anterior MI received either
amipril titrated to a dose of 10 mg from day 1 after MI
ithin the first 14 days (full dose), 0.625 mg of ramipril
rom day 1 (low dose), or placebo (2). A significantly greater
mprovement in EF and less increase in LV diastolic
imensions over the course of 14 days (echocardiography)
ere observed with ramipril in a dose-dependent manner
Fig. 1). Importantly, benefit from ramipril treatment ap-
eared to be greatest in subjects with the lowest baseline EF.
An echocardiographic substudy of the VALIANT (Val-
artan in Acute Myocardial Infarction Trial), in which
alsartan treatment and treatment with captopril resulted in
comparable incidence of cardiovascular events after AMI
ver a median of 24.7 months of follow-up, demonstrated
imilar effects of captopril and valsartan on changes in
ardiac functional parameters over time (Fig. 1) (3).
eta-blockers after AMI. The CAPRICORN (Carvedilol
ost-Infarct Survival Control in Left Ventricular Dysfunc-
ion) study was a randomized, controlled trial (n 1,959) in
hich researchers investigated the application of the beta-
locker carvedilol in addition to optimal medical treatment
n patients with LV dysfunction (EF 40%) after AMI
27). All-cause mortality was significantly lower in the
arvedilol group (12%) in comparison with the placebo
Follow-up 12 months
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Figure 1 Changes in Left Ventricular Echocardiographic Ejectio
Changes in left ventricular echocardiographic ejection fraction from baseline to fol
Enlargement) study (26), in the HEART (Healing and Early Afterload Reducing Thera
and in the CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular D
from changes in measured areas was used [here also termed ejection fraction].)roup (15%, p  0.03). In an echocardiographic substudy,
wncluding 127 patients from the CAPRICORN trial, LV
nd-systolic volumes decreased significantly more in the carve-
ilol group (–4.8  4.9 ml vs. 4.5  2.8 ml at 6 months,
arvedilol vs. placebo: p  0.023), and EF increased
ignificantly more in the carvedilol group (5.0  1.1% vs.
1.0  1.2%, carvedilol vs. placebo: p  0.015) (Fig. 1).
onclusions
any of the treatment options for AMI, as validated in
everal large-scale investigations in the past, are associated
ith a moderate increase in EF that is accompanied by a
mall reduction of LV dimensions. Putting these effects in
erspective with achievements by transplantation of periph-
ral blood- or bone marrow-derived cells, as summarized in
able 1, demonstrates a very similar variability among trials,
mphasizes the extreme importance of adequately consider-
ng changes in LV parameters over time within the respec-
ive control group, and reveals that improvements in EF
chieved by cell transplantation are within an intriguingly
imilar range compared with established therapeutic strategies.
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